Revolution Medicines
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 378
- Market Cap
- $7.2B
- Website
- http://www.revmed.com
- Introduction
Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Revolution Medicines Reports Promising Results for Zoldonrasib in KRAS G12D Mutant Lung Cancer
• Revolution Medicines announced new clinical data for zoldonrasib (RMC-9805) showing a 61% objective response rate in patients with KRAS G12D mutant non-small cell lung cancer at the AACR Annual Meeting.
• The RAS(ON) G12D-selective inhibitor demonstrated an acceptable safety profile with primarily Grade 1 or 2 adverse events and a favorable mean dose intensity of 98% in the Phase 1 study.
• These results build on earlier promising data in pancreatic ductal adenocarcinoma, supporting further evaluation of zoldonrasib as both monotherapy and in combination treatments for these difficult-to-treat cancers.
AACR Annual Meeting 2025 to Bridge Gap Between Cancer Science and Clinical Practice
• The American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago will focus on "Unifying Cancer Science and Medicine" with presentations spanning from basic research to practice-changing clinical trials.
• Program chairs Dr. Lillian Siu and Dr. Matthew Vander Heiden emphasize cross-disciplinary collaboration, encouraging attendees to explore topics outside their expertise to foster innovation in cancer research.
• Key clinical trials to be presented include promising data on zongertinib for HER2-mutant lung cancer, dostarlimab for rectal cancer, and an off-the-shelf CAR NK cell therapy for hematologic malignancies.
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
• Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
• FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer.
• Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.
Robust Pipeline of 200+ Therapies Targets Colorectal Cancer Treatment Landscape
• DelveInsight's latest report reveals a robust pipeline with over 195 companies developing 200+ therapies for colorectal cancer, highlighting significant innovation in targeted treatments and immunotherapies.
• Key drug candidates include XL092 (Exelixis), Adagrasib (Mirati Therapeutics), Olaparib (Merck/AstraZeneca), and novel approaches like LYL845, an autologous tumor-infiltrating lymphocyte therapy from Lyell Immunopharma.
• The metastatic colorectal cancer segment shows particular promise with 150+ companies advancing 180+ pipeline therapies, including innovative treatments targeting specific mutations and immune pathways.
Revolution Medicines' Novel Drug Shows Promise in Advanced Pancreatic Cancer Treatment
• A groundbreaking experimental drug, daraxonrasib by Revolution Medicines, demonstrates encouraging results in treating late-stage pancreatic cancer patients, offering new hope in a traditionally difficult-to-treat disease.
• One stage-four pancreatic cancer patient has achieved a remarkable 17-month survival while participating in the clinical trial, significantly exceeding typical survival expectations for advanced cases.
• The development represents a potential breakthrough in pancreatic cancer treatment, where current five-year survival rates for late-stage patients stand at only 3%, with median survival under one year.
Tango Therapeutics' TNG462 Receives Orphan Drug Status for Pancreatic Cancer as Company Advances PRMT5 Inhibitor Programs
• Tango Therapeutics' lead candidate TNG462 has been granted Orphan Drug Designation by the FDA for pancreatic cancer treatment, providing seven years of market exclusivity upon approval.
• The company's second PRMT5 inhibitor, TNG456, received FDA clearance for its IND application and will begin Phase 1/2 trials in early 2025, including a collaboration with Eli Lilly combining it with Verzenio.
• Key clinical data for TNG462 monotherapy focusing on pancreatic and lung cancers is expected later in 2025, with plans to initiate a registrational study in pancreatic cancer by 2026.
FDA Grants Breakthrough Therapy Status to Radiprodil for GRIN-Related Seizure Treatment
• GRIN Therapeutics' radiprodil receives FDA Breakthrough Therapy designation for treating seizures in patients with GRIN-related neurodevelopmental disorder, showing 86% median reduction in seizure frequency during Phase 1b trials.
• The investigational drug demonstrated significant efficacy in Phase 1b Honeycomb study, with 71% of patients achieving over 50% reduction in countable motor seizures and most patients showing behavioral improvements.
• The company plans to initiate Phase 3 pivotal trials in mid-2025, backed by a $200M capital commitment from Blackstone Life Sciences, to evaluate radiprodil's impact on seizures and behavioral outcomes.
FDA Approves Lumakras and Vectibix Combination for KRAS G12C-Mutated Metastatic Colorectal Cancer
• The FDA has approved Lumakras (sotorasib) combined with Vectibix (panitumumab) for treating KRAS G12C-mutated metastatic colorectal cancer in adults after prior chemotherapy.
• CodeBreaK 300 trial data showed the combination significantly improved progression-free survival compared to standard of care in chemorefractory patients.
• Patients on Lumakras and Vectibix had a median progression-free survival of 5.6 months, compared to 2 months on standard of care, with a 26% overall response rate.
• This approval provides a new targeted treatment option for a subset of colorectal cancer patients with limited alternatives, emphasizing the importance of biomarker testing.
Novel KRAS-Targeting Agents Show Promise in Clinical Trials for Advanced Cancers
• Roswell Park Comprehensive Cancer Center is conducting clinical trials for new KRAS-targeting agents that offer alternative approaches to treating KRAS-mutated cancers.
• One trial involves an agent that directly breaks down the KRAS molecule, effectively cutting off the signal for cell growth in cancers with the G12D mutation.
• Another trial combines a novel agent, ezurpimtrostat, with trametinib to target any KRAS mutation in bile duct cancer, aiming to block cancer cell survival mechanisms.
• These trials mark a significant step forward, providing targeted options for patients with KRAS mutations, which were previously considered 'undruggable'.
Arvinas Advances Vepdegestrant into Phase 3 Trials for Breast Cancer and Updates Pipeline Milestones
• Arvinas plans to initiate two Phase 3 trials in 2025 for vepdegestrant in ER+/HER2- metastatic breast cancer, one in the first-line setting with atirmociclib and another in the second-line setting with a CDK4/6 inhibitor.
• Topline data from the Phase 3 VERITAC-2 monotherapy trial of vepdegestrant in second-line-plus ER+/HER2- metastatic breast cancer is anticipated in the first quarter of 2025.
• Arvinas is set to present initial data from the Phase 1 trial of ARV-393 in B-cell lymphomas and file an IND application for a novel PROTAC KRAS G12D degrader in 2025.
• Phase 1 trial with PROTAC LRRK2 degrader ARV-102 in patients with Parkinson’s disease has been initiated, with data expected to be presented in the first half of 2025.
Personalized mRNA Vaccine Shows Promise in Delaying Pancreatic Cancer Recurrence
• A Phase 1 clinical trial reveals that a personalized mRNA vaccine, autogene cevumeran, combined with surgery and chemotherapy, shows promise in delaying pancreatic cancer recurrence.
• The vaccine stimulates long-lasting T cell responses, with patients who developed these responses experiencing a significantly longer recurrence-free survival compared to non-responders.
• The study highlights the potential of mRNA vaccines to train the immune system to recognize and attack pancreatic cancer cells, offering a new therapeutic avenue for this challenging disease.
• Larger studies are planned to further evaluate the effectiveness of these therapeutic cancer vaccines in patients with surgically removable pancreatic cancer.
BioNTech's Bispecific Antibody BNT-327 Shows Promise in Triple-Negative Breast Cancer
• BioNTech's BNT-327, a bispecific antibody targeting PD-L1 and VEGF, has demonstrated positive early results in patients with triple-negative breast cancer.
• The bispecific antibody builds on the success of checkpoint inhibitors like Keytruda, potentially representing the next generation of immunotherapy drugs.
• Early trial data, presented at the San Antonio Breast Cancer Symposium, suggest BNT-327 could become a critical component in treating triple-negative breast cancer.
• The development of BNT-327 aligns with a broader interest in PD1/PD-L1 and anti-VEGF bispecifics, following promising results from Summit Therapeutics in lung cancer.
Relay Therapeutics' RLY-2608: A Mutant-Selective PI3Kα Inhibitor Enters Phase I Trials for HR+/HER2- Breast Cancer
• RLY-2608, an oral, mutant-selective PI3Kα inhibitor developed by Relay Therapeutics, is currently undergoing Phase I clinical trials.
• The drug is being evaluated both as a single agent and in combination with fulvestrant for the treatment of HR+/HER2- breast cancer.
• RLY-2608 aims to overcome toxicities associated with wild-type PI3Kα inhibition, a limitation of existing PI3Kα modulators like alpelisib and inavolisib.
• This innovative molecule targets specific PI3Kα mutations, potentially reducing side effects such as hyperglycemia and rash observed with less selective inhibitors.
Revolution Medicines' RMC-6236 Shows Promise in RAS-Addicted Cancers
• Revolution Medicines reports RMC-6236 demonstrates encouraging safety and efficacy in Phase 1/1b trials for pancreatic and lung cancers.
• In pancreatic cancer, RMC-6236 monotherapy achieved a median progression-free survival of 8.8 months in KRAS G12X-mutated patients.
• For lung cancer, RMC-6236 showed a median PFS of 9.8 months in patients who had undergone immunotherapy and platinum chemotherapy.
• Revolution Medicines plans to advance RMC-6236 into Phase 3 trials for both metastatic pancreatic and lung cancers in 2025.
Tango Therapeutics' PRMT5 Inhibitor TNG462 Shows Promise in Early Trials, Combination Studies Planned
• Tango Therapeutics' TNG462 demonstrates clinical activity in NSCLC and pancreatic cancer, with a 43% ORR in cholangiocarcinoma, showcasing a favorable safety profile.
• Tango plans to initiate combination trials of TNG462 with RAS(ON) inhibitors from Revolution Medicines, osimertinib, and pembrolizumab in 1H 2025.
• TNG908 shows clinical activity in non-CNS cancers, particularly pancreatic cancer, but development is deprioritized in favor of TNG462 due to its superior profile.
• Tango's next-generation brain-penetrant PRMT5 inhibitor, TNG456, is set to begin phase 1/2 trials in 1H 2025, targeting glioblastoma and brain metastases.
Cell Therapy and Targeted Therapies Dominate Oncology Advances in Early 2025
• The FDA issued a CRL for Atara Biotherapeutics' tabelecleucel due to third-party manufacturing issues, not efficacy or safety data, delaying potential approval for EBV+ PTLD.
• EsoBiotec dosed the first patient in a trial for ESO-T01, an in vivo BCMA-directed CAR-T therapy for multiple myeloma, aiming for lower costs and simplified administration.
• Obecabtagene autoleucel (obe-cel) gained FDA approval for relapsed/refractory B-cell precursor ALL, offering a less toxic CD19-directed CAR T-cell therapy option.
• Arlocabtagene autoleucel (arlo-cel) shows promise in heavily pretreated relapsed/refractory multiple myeloma, eliciting a 48% complete response rate in phase 1 studies.
AstraZeneca Secures KRAS G12D Inhibitor in $419M Deal with Usynova
• AstraZeneca has licensed UA022, a novel KRAS G12D inhibitor, from Chinese biotech Usynova for $24 million upfront, with potential milestone payments reaching $395 million.
• The preclinical compound targets KRAS G12D mutations, which account for 26% of all KRAS mutations and are commonly found in pancreatic and colorectal cancers, addressing a significant unmet medical need.
• This strategic move positions AstraZeneca among select companies developing KRAS G12D inhibitors, including Mirati, Revolution Medicines, and Roche/Chugai, expanding the frontier of precision oncology.
© Copyright 2025. All Rights Reserved by MedPath